# A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

> **NCT05261269** · PHASE1 · COMPLETED · sponsor: **Dantari, Inc.** · enrollment: 30 (actual)

## Conditions studied

- HER2-negative Metastatic Breast Cancer

## Interventions

- **DRUG:** DAN-222
- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT05261269
- **Lead sponsor:** Dantari, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-02
- **Primary completion:** 2023-09-13
- **Final completion:** 2023-10-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05261269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05261269, "A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05261269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*